Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Bio-Techne Corporation TECH
$80.64
-$1.2 (-1.48%)
На 18:00, 12 мая 2023
+26.39%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
12743207523.00000000
-
week52high
99.34
-
week52low
68.00
-
Revenue
1105599000
-
P/E TTM
50
-
Beta
1.25224900
-
EPS
1.61000000
-
Last Dividend
0.32000000
-
Next Earnings Date
02 авг 2023 г. в 12:30
Описание компании
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Outperform | 25 авг 2022 г. | |
| Wells Fargo | Underweight | Underweight | 16 авг 2022 г. |
| Stephens & Co. | Overweight | Overweight | 05 авг 2022 г. |
| Keybanc | Overweight | Overweight | 05 мая 2022 г. |
| Wells Fargo | Underweight | Equal-Weight | 25 апр 2022 г. |
| SVB Leerink | Outperform | Outperform | 02 ноя 2022 г. |
| RBC Capital | Sector Perform | 07 дек 2022 г. | |
| Stephens & Co. | Overweight | Overweight | 05 дек 2022 г. |
| Wells Fargo | Equal-Weight | Underweight | 10 янв 2023 г. |
| Deutsche Bank | Buy | 14 дек 2022 г. | |
| Citigroup | Buy | Neutral | 12 дек 2022 г. |
| SVB Leerink | Outperform | Outperform | 03 февр 2023 г. |
| Keybanc | Overweight | Overweight | 03 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kummeth Charles R. | A | 1368976 | 407364 | 04 янв 2023 г. |
| Kummeth Charles R. | D | 616676 | 407364 | 04 янв 2023 г. |
| Kummeth Charles R. | D | 1113139 | 255837 | 04 янв 2023 г. |
| Furlow Brenda S. | D | 29762 | 7450 | 08 дек 2022 г. |
| Furlow Brenda S. | D | 26092 | 7450 | 08 дек 2022 г. |
| Furlow Brenda S. | A | 33542 | 7450 | 08 дек 2022 г. |
| Furlow Brenda S. | D | 37212 | 800 | 07 дек 2022 г. |
| Furlow Brenda S. | D | 26092 | 800 | 07 дек 2022 г. |
| Furlow Brenda S. | A | 26892 | 800 | 07 дек 2022 г. |
| HIGGINS JOHN L | A | 865 | 865 | 27 окт 2022 г. |
Новостная лента
BIO-TECHNE TO PRESENT AT THE 2023 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
PRNewsWire
12 мая 2023 г. в 09:07
MINNEAPOLIS , May 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 2:35 p.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Bio-Techne Corporation (TECH) Q3 2023 Earnings Call Transcript
Seeking Alpha
03 мая 2023 г. в 15:39
Bio-Techne Corporation (NASDAQ:TECH ) Q3 2023 Earnings Conference Call May 3, 2023 9:00 AM ET Company Participants David Clair – Vice President-Investor Relations Chuck Kummeth – Chief Executive Officer Jim Hippel – Chief Financial Officer Conference Call Participants Puneet Souda – SVB Securities Jacob Johnson – Stephens Dan Arias – Stifel Dan Leonard – Credit Suisse Patrick Donnelly – Citi Catherine Schulte – Baird Justin Bowers – Deutsche Bank Alex Nowak – Craig-Hallum Operator Good day, and welcome to the Bio-Techne Corp Third Quarter Fiscal 2023 Earnings Call. All participants will be in a listen-only mode.
Techne (TECH) Meets Q3 Earnings Estimates
Zacks Investment Research
03 мая 2023 г. в 09:07
Techne (TECH) came out with quarterly earnings of $0.53 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.54 per share a year ago.
GSK or TECH: Which Is the Better Value Stock Right Now?
Zacks Investment Research
28 апр 2023 г. в 12:56
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both GSK (GSK) and Techne (TECH). But which of these two companies is the best option for those looking for undervalued stocks?
7 Biotech Stocks That Could Cure Your Portfolio Woes
InvestorPlace
19 апр 2023 г. в 19:22
Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).